In general, most of the patients (70.0%) completed the full course (6 cycles) of NAC, and relatively high tpCR (48%) and bpCR (60%) were attained in the present study, which demonstrated that PLD plus docetaxel and trastuzumab might be a potential neoadjuvant regimen for HER2-positive BC. Here, ERBB2 is linked to breast cancer.